Does Lp-PLA2 drive local plaque inflammation and predict higher cardiovascular risk?

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a vascular-specific enzyme that plays a critical role in the microenvironment of atherosclerotic plaques, serving as both a local driver of inflammation and an independent biomarker of cardiovascular risk.

Mechanistic pathways of vascular inflammation

• Plaque localization: Lp-PLA2 is synthesized locally within the arterial intima by inflammatory cells—predominantly macrophages, foam cells, monocytes, and T lymphocytes. It highly co-localizes with oxidized low-density lipoprotein (LDL) in rupture-prone areas like the necrotic core and plaque shoulders.
• Enzymatic cleavage: The enzyme specifically targets oxidized phospholipids on LDL particles, hydrolyzing the sn-2 ester bond.
• Pro-inflammatory cascade: This cleavage generates two highly bioactive mediators: lysophosphatidylcholine (LysoPC) and oxidized non-esterified fatty acids (oxNEFAs). LysoPC acts as a potent chemoattractant, recruiting monocytes to the intima, promoting M1 macrophage polarization, and stimulating endothelial adhesion molecules (such as VCAM-1 and ICAM-1).
• Feed-forward loop: Unhydrolyzed oxidized phospholipids on LDL upregulate the expression of Lp-PLA2 in macrophages via PI3K and p38 MAPK signaling pathways, perpetuating local vascular inflammation and plaque instability.

Clinical evidence and cardiovascular risk

• Vascular specificity: Unlike systemic inflammatory markers, elevated Lp-PLA2 activity directly reflects active, localized vascular inflammation and plaque vulnerability.
• Risk correlation: A collaborative meta-analysis of 32 prospective studies involving approximately 80,000 participants demonstrated a continuous, graded association, with a relative risk of roughly 1.10 per standard deviation increase in Lp-PLA2 activity for coronary heart disease and ischemic stroke.
• Plaque progression: Large prospective cohorts, such as the Malmö study, show that individuals in the highest tertiles or quartiles of Lp-PLA2 activity experience a 1.5- to nearly 2-fold increased risk of incident coronary events and stroke compared to those in the lowest categories.

Bottom line

• Lp-PLA2 is synthesized by plaque-associated inflammatory cells and hydrolyzes oxidized LDL to produce highly pro-inflammatory LysoPC and oxNEFAs, establishing a localized inflammatory loop. Elevated Lp-PLA2 activity is a validated, vascular-specific biomarker that independently predicts a significantly higher risk of coronary heart disease and ischemic stroke.